Outcomes Following Transcatheter Mitral Valve Replacement Using Dedicated Devices in Patients With Mitral Annular Calcification
JACC: Cardiovascular Interventions · 2024
DOI: 10.1016/j.jcin.2024.07.038 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2024. Verfasst von Augustin Coisne und 40 weiteren Autor:innen. Beteiligte Einrichtung: University Lille, Inserm, CHU Lille, Institut Pasteur de Lille, Lille, France; Cardiovascular Research Foundation, New York, New York, USA. Electroni…. Hauptthemen laut MEDLINE: Calcinosis, Cardiac Catheterization, Feasibility Studies, Heart Valve Prosthesis. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Patients with mitral regurgitation (MR) and morphologic presence of relevant mitral annular calcification (MAC) represent a challenging phenotypic subset with limited treatment options. OBJECTIVES: The aim of this study was to assess the feasibility of transcatheter mitral valve replacement (TMVR) using dedicated devices for the treatment of MAC patients. METHODS: Consecutive patients with symptomatic MR receiving TMVR and with available computed tomography data from the CHOICE-MI (Choice of Optimal Transcatheter Treatment for Mitral Insufficiency) multicenter registry were stratified by the presence of none or mild mitral annular calcification (MACnone/mild) vs moderate or severe mitral annular calcification (MACmod/sev). RESULTS: Among 279 eligible patients (median age = 76.0 years [Q1-Q3: 71.0-81.0 years], EuroSCORE II = 6.2% [Q1-Q3: 3.9%-12.1%]), 222 (79.6%) presented with MACnone/mild and 57 (20.4%) with MACmod/sev. Patients with MACmod/sev had a higher prevalence of extracardiac arteriopathy (P = 0.011) and primary MR (P < 0.001). Although the technical success rate and the extent of MR elimination did not differ, TMVR treatment in MACmod/sev patients was associated with higher rates of postprocedural bleeding complications (P = 0.02) and renal failure (P < 0.001). Functional improvement at the 1- and 2-year follow-up did not differ between groups. At the 2-year follow-up, there were no differences between patients with MACmod/sev and MACnone/mild regarding all-cause mortality (38.5% vs 37.7%; P = 0.76), cardiovascular mortality (21.3% vs 24.9%; P = 0.97), and all-cause mortality or heart failure hospitalization (52.4% vs 46.7%; P = 0.28) CONCLUSIONS: TMVR in patients with MACmod/sev is associated with higher rates of postprocedural complications but similar rates of survival, MR resolution, and functional improvement compared to MACnone/mild. Further studies are necessary to define the role of dedicated TMVR devices in this population. (Choice of Optimal Transcatheter Treatment for Mitral Insufficiency Registry [CHOICE-MI]; NCT04688190).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University Lille, Inserm, CHU Lille, Institut Pasteur de Lille, Lille, France; Cardiovascular Research Foundation, New York, New York, USA. Electronic address: augustin.coisne@chu-lille.fr.
- Cardiovascular Research Foundation, New York, New York, USA; Department of Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany; German Center for Cardiovascular Research, Partner Site Hamburg/Kiel…
- Cardiovascular Research Foundation, New York, New York, USA; Montefiore Medical Center, Montefiore-Einstein Center for Heart and Vascular Care, New York, New York, USA.
- Structural Valve Program, Montreal Heart Institute, Montréal, Canada.
- Department of Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany.
- Royal Brompton Hospital, London, United Kingdom.
Zitieren
APA
Coisne, A., Ludwig, S., Scotti, A., Ben Ali, W., Weimann, J., Duncan, A., Webb, J. G., Kalbacher, D., Rudolph, T. K., Nickenig, G., Hausleiter, J., Ruge, H., Adam, M., Petronio, A. S., Dumonteil, N., Søndergaard, L., Adamo, M., Regazzoli, D., Garatti, A., …, & CHOICE-MI Investigators (2024). Outcomes Following Transcatheter Mitral Valve Replacement Using Dedicated Devices in Patients With Mitral Annular Calcification. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2024.07.038
Vancouver
Coisne A, Ludwig S, Scotti A, Ben Ali W, Weimann J, Duncan A, et al. Outcomes Following Transcatheter Mitral Valve Replacement Using Dedicated Devices in Patients With Mitral Annular Calcification. JACC: Cardiovascular Interventions. 2024. doi:10.1016/j.jcin.2024.07.038
BibTeX
@article{Coisne2024,
author = {Coisne, Augustin and Ludwig, Sebastian and Scotti, Andrea and Ben Ali, Walid and Weimann, Jessica and Duncan, Alison and Webb, John G and Kalbacher, Daniel and Rudolph, Tanja K and Nickenig, Georg and Hausleiter, Jörg and Ruge, Hendrik and Adam, Matti and Petronio, Anna S and Dumonteil, Nicolas and Søndergaard, Lars and Adamo, Marianna and Regazzoli, Damiano and Garatti, Andrea and Schmidt, Tobias and Dahle, Gry and Taramasso, Maurizio and Walther, Thomas and Kempfert, Joerg and Obadia, Jean-François and Redwood, Simon and Tang, Gilbert H L and Goel, Sachin and Fam, Neil and Metra, Marco and Andreas, Martin and Muller, David W and Denti, Paolo and Praz, Fabien and von Bardeleben, Ralph Stephan and Leroux, Lionel and Latib, Azeem and Granada, Juan F and Conradi, Lenard and Modine, Thomas and CHOICE-MI Investigators, CHOICE-MI Investigators},
title = {Outcomes Following Transcatheter Mitral Valve Replacement Using Dedicated Devices in Patients With Mitral Annular Calcification},
journal = {JACC: Cardiovascular Interventions},
year = {2024},
doi = {10.1016/j.jcin.2024.07.038}
}
EUVIMED